应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
未开盘 07-28 16:09:10
2.520
+0.080
+3.28%
最高
2.550
最低
2.350
成交量
715.00万
今开
2.450
昨收
2.440
日振幅
8.20%
总市值
11.28亿
流通市值
11.28亿
总股本
4.47亿
成交额
1,762万
换手率
1.60%
流通股本
4.47亿
市净率
3.51
ROE
-41.29%
每股收益
-0.39
52周最高
2.970
52周最低
0.790
市盈率
-6.39
股息
0.00
股息收益率
0.00
ROA
-13.17%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
亚虹医药公布国际专利申请:“USP1抑制剂及其医药用途”
证券之星 · 46分钟前
亚虹医药公布国际专利申请:“USP1抑制剂及其医药用途”
百花医药:公司作为专注于小分子化学药领域的医药研发合同研究机构
证券之星 · 10:21
百花医药:公司作为专注于小分子化学药领域的医药研发合同研究机构
复宏汉霖(02696):地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见
智通财经 · 10:17
复宏汉霖(02696):地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见
开拓药业-B07月28日获主力加仓121.4万元
市场透视 · 08:15
开拓药业-B07月28日获主力加仓121.4万元
华昊中天医药-B07月28日主力净流出21.4万元 散户资金买入
市场透视 · 08:15
华昊中天医药-B07月28日主力净流出21.4万元 散户资金买入
新股前瞻|核心产品尚处研发早期,如何看待亦诺微医药管线“含金量”?
智通财经 · 07:43
新股前瞻|核心产品尚处研发早期,如何看待亦诺微医药管线“含金量”?
ETF午评 | 创新药板块强势上涨,创新药ETF天弘、药ETF涨2%
格隆汇 · 03:40
ETF午评 | 创新药板块强势上涨,创新药ETF天弘、药ETF涨2%
白云山(00874.HK)子公司中期票据和超短期融资券获准注册
智通财经 · 07-25
白云山(00874.HK)子公司中期票据和超短期融资券获准注册
恒瑞医药(01276.HK)拟4001.44 万元收购控股子公司成都盛迪1.4587%股权
智通财经 · 07-25
恒瑞医药(01276.HK)拟4001.44 万元收购控股子公司成都盛迪1.4587%股权
7月25日博腾股份涨7.55%,天弘医药创新A基金重仓该股
证券之星 · 07-25
7月25日博腾股份涨7.55%,天弘医药创新A基金重仓该股
A股市场活跃度上升明显!三大利好,医药、医疗器械板块突然引爆
券商中国 · 07-25
A股市场活跃度上升明显!三大利好,医药、医疗器械板块突然引爆
医药板块也“反内卷”!CXO、医疗器械接棒反攻,创新药ETF天弘(517380)、医疗设备ETF(159873)涨超1%
格隆汇 · 07-25
医药板块也“反内卷”!CXO、医疗器械接棒反攻,创新药ETF天弘(517380)、医疗设备ETF(159873)涨超1%
港股异动 | 中生制药(01177.HK)再涨超4% 附属礼新医药LM-350获得美国FDA的IND批件
智通财经 · 07-25
港股异动 | 中生制药(01177.HK)再涨超4% 附属礼新医药LM-350获得美国FDA的IND批件
同源康医药-B(02410.HK):TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录
智通财经 · 07-24
同源康医药-B(02410.HK):TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录
同源康医药-B(02410):TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录
智通财经 · 07-24
同源康医药-B(02410):TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录
华昊中天医药-B(02563.HK)委任大信会计师事务所(特殊普通合伙)为核数师
智通财经 · 07-24
华昊中天医药-B(02563.HK)委任大信会计师事务所(特殊普通合伙)为核数师
华昊中天医药-B委任大信为公司新核数师
格隆汇 · 07-24
华昊中天医药-B委任大信为公司新核数师
KT International Investment Limited增持开拓药业-B(09939)50万股 每股作价2.598港元
智通财经 · 07-24
KT International Investment Limited增持开拓药业-B(09939)50万股 每股作价2.598港元
桂林三金:7月23日接受机构调研,长江证券医药参与
证券之星 · 07-24
桂林三金:7月23日接受机构调研,长江证券医药参与
恒瑞医药(01276.HK)子公司HRS-1893片获得药物临床试验批准通知书
智通财经 · 07-24
恒瑞医药(01276.HK)子公司HRS-1893片获得药物临床试验批准通知书
加载更多
公司概况
公司名称:
开拓药业-B
所属市场:
SEHK
上市日期:
2020-05-22
主营业务:
开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
发行价格:
20.150
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.52,"timestamp":1753690150655,"preClose":2.44,"halted":0,"volume":7150000,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-0.394183195695346,"marketStatus":"未开盘","change":0.08,"latestTime":"07-28 16:09:10","open":2.45,"high":2.55,"low":2.35,"amount":17622156,"amplitude":0.081967,"askPrice":2.53,"askSize":33000,"bidPrice":2.52,"bidSize":15500,"shortable":0,"etf":0,"ttmEps":-0.394183195695346,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753752600000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.44,"openAndCloseTimeList":[[1753666200000,1753675200000],[1753678800000,1753689600000]],"volumeRatio":0.7086650166406097,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2555970112","title":"亚虹医药公布国际专利申请:“USP1抑制剂及其医药用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2555970112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555970112?lang=zh_cn&edition=full","pubTime":"2025-07-29 04:55","pubTimestamp":1753736116,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示亚虹医药(688176)公布了一项国际专利申请,专利名为“USP1抑制剂及其医药用途”,专利申请号为PCT/CN2025/073034,国际公布日为2025年7月24日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来亚虹医药已公布的国际专利申请4个,较去年同期减少了20%。结合公司2024年年报财务数据,2024年公司在研发方面投入了3.12亿元,同比减14.45%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900005088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","BK1161","09939","688176","BK1574","159938"],"gpt_icon":0},{"id":"2554977860","title":"百花医药:公司作为专注于小分子化学药领域的医药研发合同研究机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2554977860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554977860?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:21","pubTimestamp":1753698076,"startTime":"0","endTime":"0","summary":"公司作为专注于小分子化学药领域的医药研发合同研究机构,商业模式是为客户提供涵盖临床前研究至上市后临床研究全流程的委托研发服务。上述布局旨在帮助客户实现从仿制药开发向改良型新药及更高技术复杂度仿制药升级的技术需求,提升客户委托项目的研发效率与成功率,最终研发成果均归属客户所有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800026786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0102","BK1161","600721","09939","BK1574","BK0216","159938"],"gpt_icon":0},{"id":"2554877836","title":"复宏汉霖(02696):地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877836","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877836?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:17","pubTimestamp":1753697873,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖(02696)发布公告,近日,HLX14获EMA人用医药产品委员会(Committee for Medicinal Products for Human Use,“CHMP”)积极审评意见,推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会(European Commission,“EC”),EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准,HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA)国家冰岛、列支敦士登和挪威生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4081","CHMP","EMA","BK4087","BK1161","09939","02696","BK1574","159938"],"gpt_icon":0},{"id":"2554771079","title":"开拓药业-B07月28日获主力加仓121.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554771079","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554771079?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:15","pubTimestamp":1753690552,"startTime":"0","endTime":"0","summary":"07月28日, 开拓药业-B股价涨3.28%,报收2.52元,成交金额1762.2万元,换手率1.60%,振幅8.20%,量比0.71。开拓药业-B今日主力资金净流入121.4万元,上一交易日主力净流入121.6万元。该股近5个交易日上涨4.56%,主力资金累计净流出106.2万元;近20日主力资金累计净流入197.2万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165840a4676360&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165840a4676360&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2554773586","title":"华昊中天医药-B07月28日主力净流出21.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2554773586","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554773586?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:15","pubTimestamp":1753690533,"startTime":"0","endTime":"0","summary":"07月28日, 华昊中天医药-B股价跌0.62%,报收7.96元,成交金额142.0万元,换手率0.08%,振幅5.99%,量比3.12。华昊中天医药-B今日主力资金净流出21.4万元,上一交易日主力净流出0万元。该股近5个交易日下跌2.92%,主力资金累计净流出21.4万元;近20日主力资金累计净流出310.6万元,其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165221a4675fb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165221a4675fb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1161","09939","02563"],"gpt_icon":0},{"id":"2554729880","title":"新股前瞻|核心产品尚处研发早期,如何看待亦诺微医药管线“含金量”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2554729880","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554729880?lang=zh_cn&edition=full","pubTime":"2025-07-28 15:43","pubTimestamp":1753688587,"startTime":"0","endTime":"0","summary":"在此情形下,一家专注“小众”赛道的创新药企业赴港上市,获得市场密切关注:近日,亦诺微医药向港交所主板提交上市申请,花旗、中金公司为其联席保荐人。公开信息显示,目前公司并无获批上市或商业化的药品,报告期内持续处于亏损状态。其中,核心产品的研发开支分别占同期研发开支总额的79.2%、67.7%和52.8%,主要因临床开发进度相关的试验及测试开支减少所致。财务状况紧张,或也成为亦诺微医药急于赴港上市的原因之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","09939","159938","BK1574"],"gpt_icon":0},{"id":"2554174741","title":"ETF午评 | 创新药板块强势上涨,创新药ETF天弘、药ETF涨2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554174741","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554174741?lang=zh_cn&edition=full","pubTime":"2025-07-28 11:40","pubTimestamp":1753674048,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01336","BK0188","513750","399001","BK1184","09939","159930","516020","BK1574","515220","PCB","161024","BK0207","BK1161","BK0028","BK4550","159227","BK0196","159992","515120","BK4211","159945","SG9999006597.SGD","159940","BK1584","601336","BK0183","FDN","BK1515","000680.SH","562050","BK1550","06978","BK0012","159938","159982","159392","399006","561260","399300","BK4588","161032","159870","BK4585"],"gpt_icon":0},{"id":"2554842762","title":"白云山(00874.HK)子公司中期票据和超短期融资券获准注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2554842762","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554842762?lang=zh_cn&edition=full","pubTime":"2025-07-25 19:53","pubTimestamp":1753444381,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0015","LU0307460666.USD","BK0028","LU1634259391.SGD","BK0012","BK1521","LU0651947912.USD","BK1515","BK1606","LU2097828631.EUR","LU2097828474.EUR","BK1191","03988","159938","LU0293314216.USD","SG9999001093.SGD","600332","IE00BWDBJ730.SGD","LU1282651121.HKD","BK0188","LU2097828805.USD","LU0651946864.USD","LU1048588211.SGD","BK0097","BK0070","LU1224444064.USD","LU2097828714.EUR","03143","LU1497734951.SGD","LU0348805143.USD","LU1051768304.USD","LU1515016050.SGD","LU1522347837.USD","LU1497733631.SGD","BK0196","LU1282651048.USD","LU1634259557.SGD","601988","BK0183","LU2097828557.USD","BK1197","LU0588546209.SGD","IE00BQJZWZ67.USD","BK1574","BK1231","SG9999006597.SGD","BK0239","LU1497733557.USD","09939","00874"],"gpt_icon":0},{"id":"2554765228","title":"恒瑞医药(01276.HK)拟4001.44 万元收购控股子公司成都盛迪1.4587%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2554765228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554765228?lang=zh_cn&edition=full","pubTime":"2025-07-25 18:07","pubTimestamp":1753438055,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1328615791.USD","LU0405327148.USD","LU1997245094.SGD","BK1515","LU2148510915.USD","LU2488822045.USD","BK0196","600276","LU2328871848.SGD","LU1969619763.USD","BK0028","LU1064130708.USD","BK0183","LU1064131003.USD","LU1997245177.USD","BK1161","BK1191","01276","LU1997244956.HKD","BK1574","09939","159938","BK0060","BK0188","BK0239","LU0405327494.USD","BK0012","LU2495084118.USD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2554757836","title":"7月25日博腾股份涨7.55%,天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554757836","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554757836?lang=zh_cn&edition=full","pubTime":"2025-07-25 16:22","pubTimestamp":1753431742,"startTime":"0","endTime":"0","summary":"证券之星消息,7月25日博腾股份涨7.55%创60日新高,收盘报23.66元,换手率13.05%,成交量65.31万手,成交额15.48亿元。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共12家,其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为7.07亿元,最新净值1.0331,较上一交易日上涨3.55%,近一年上涨57.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500025866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300363","09939","BK1515","159938","BK1574","BK0028","BK0239","BK1161"],"gpt_icon":0},{"id":"2554757368","title":"A股市场活跃度上升明显!三大利好,医药、医疗器械板块突然引爆","url":"https://stock-news.laohu8.com/highlight/detail?id=2554757368","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554757368?lang=zh_cn&edition=full","pubTime":"2025-07-25 14:04","pubTimestamp":1753423440,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 最近,A股市场的活跃度上升明显! 7月25日,A股三大指数小幅震荡,前期涨幅较大的板块出现调整,AI概念股集体走强。此外,医药、医疗器械板块也大幅冲高,易明医药、天目药业、誉衡药业、康泰医学、正川股份等盘中直线拉升至涨停。 除了上述利好消息外,医药、医疗器械板块最近两天也迎来了另外两则利好消息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-07-25/doc-infhsfmy8378496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","BK1583","159982","09997","BK1574","09939","399300","BK1161","BK1100","BK1515","159938","BK1222","159883"],"gpt_icon":0},{"id":"2554773796","title":"医药板块也“反内卷”!CXO、医疗器械接棒反攻,创新药ETF天弘(517380)、医疗设备ETF(159873)涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554773796","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554773796?lang=zh_cn&edition=full","pubTime":"2025-07-25 10:24","pubTimestamp":1753410246,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","399300","688626","300122","CXO.AU","03759","LU0979878070.USD","300869","159399","688271","07226","06127","159883","02269","09997","BK1515","161726","FDN","159646","159217","09939","515120","02196","000808.SH","09996","300832","512290","159938","300760","BK0060","600196","HSCEI","159873","159645","603127","163118","300759","601788","CXO","159859","603976","399441","06978","06178","159982","159891","YANG","HSTECH"],"gpt_icon":0},{"id":"2554327677","title":"港股异动 | 中生制药(01177.HK)再涨超4% 附属礼新医药LM-350获得美国FDA的IND批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2554327677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554327677?lang=zh_cn&edition=full","pubTime":"2025-07-25 09:59","pubTimestamp":1753408758,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","01177","BK1515","BK1521","159938","BK1574","BK1589","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","01477","BK1161","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2553789679","title":"同源康医药-B(02410.HK):TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录","url":"https://stock-news.laohu8.com/highlight/detail?id=2553789679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553789679?lang=zh_cn&edition=full","pubTime":"2025-07-24 22:51","pubTimestamp":1753368686,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159938","BK1583","BK1574","BK1161","BK1515","BK1141","03347","09939","02410","BK1576","TY"],"gpt_icon":0},{"id":"2553678967","title":"同源康医药-B(02410):TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录","url":"https://stock-news.laohu8.com/highlight/detail?id=2553678967","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553678967?lang=zh_cn&edition=full","pubTime":"2025-07-24 22:51","pubTimestamp":1753368686,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同源康医药-B 发布公告,公司自主研发的三款临床产品TY-302、 TY-2699a及TY-0540的I期临床试验结果,正式获2025年欧洲肿瘤内科学会 大会以壁报形式收录。初步临床数据显示,TY-2699a在同类剂量水平下兼具优异安全性和初步疗效。TY-0540是一种选择性CDK2抑制剂,拟用于治疗乳腺癌、卵巢癌及前列腺癌等其他实体瘤。欧洲肿瘤内科学会成立于1975年,是全球领先的肿瘤学专业学术组织。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09939","03347","BK1583","BK1141","TY","159938","BK1161","BK1576","BK1515","02410"],"gpt_icon":0},{"id":"2553278969","title":"华昊中天医药-B(02563.HK)委任大信会计师事务所(特殊普通合伙)为核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2553278969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553278969?lang=zh_cn&edition=full","pubTime":"2025-07-24 22:46","pubTimestamp":1753368404,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","159938","02563","BK1161","09939"],"gpt_icon":0},{"id":"2553789522","title":"华昊中天医药-B委任大信为公司新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2553789522","media":"格隆汇","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553789522?lang=zh_cn&edition=full","pubTime":"2025-07-24 22:39","pubTimestamp":1753367971,"startTime":"0","endTime":"0","summary":"格隆汇7月24日丨华昊中天医药-B(02563.HK)公告,大信国际(香港)会计师事务所退任公司核数师。董事会已议决于大信退任后建议委任大信会计师事务所(特殊普通合伙)为公司核数师。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072422394194b8858b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072422394194b8858b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02563","BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2553207734","title":"KT International Investment Limited增持开拓药业-B(09939)50万股 每股作价2.598港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553207734","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553207734?lang=zh_cn&edition=full","pubTime":"2025-07-24 19:54","pubTimestamp":1753358085,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,7月24日,KT International Investment Limited增持开拓药业-B(09939)50万股,每股作价2.598港元,总金额为129.9万港元。增持后最新持股数目约为4755.03万股,最新持股比例为10.63%。本次交易涉及其他关联方:Tong Youzhi。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","LU0541501648.USD","BK1574","KT","09939","BK1161","BK4115","LU0541502299.USD"],"gpt_icon":0},{"id":"2553206725","title":"桂林三金:7月23日接受机构调研,长江证券医药参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2553206725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553206725?lang=zh_cn&edition=full","pubTime":"2025-07-24 18:01","pubTimestamp":1753351311,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年7月24日桂林三金发布公告称公司于2025年7月23日接受机构调研,长江证券医药参与。基药目录公布时间由国家相关部门根据调整工作开展情况公布,目前国家暂未宣布新版基药目录公布时间。桂林三金主营业务:中成药的研发、制造与销售。桂林三金2025年一季报显示,公司主营收入4.67亿元,同比下降3.32%;归母净利润1.05亿元,同比上升4.8%;扣非净利润9767.29万元,同比上升11.61%;负债率27.69%,投资收益-35.57万元,财务费用-136.25万元,毛利率77.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400029463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","BK0028","09939","BK0060","BK0239","BK0183","BK0188","002275","000783","159938","BK1161","BK0276","BK0201"],"gpt_icon":0},{"id":"2553208164","title":"恒瑞医药(01276.HK)子公司HRS-1893片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2553208164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553208164?lang=zh_cn&edition=full","pubTime":"2025-07-24 17:03","pubTimestamp":1753347832,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1064131003.USD","LU1328615791.USD","LU1655091616.SGD","600276","LU2488822045.USD","159938","09939","BK1515","BK0196","LU1064130708.USD","03347","01276","LU2148510915.USD","LU1997245177.USD","BK1574","BK0012","BK1576","LU2328871848.SGD","LU0405327148.USD","LU2495084118.USD","LU1969619763.USD","BK0188","BK0028","BK1141","BK0060","LU1997245094.SGD","LU0405327494.USD","BK0183","BK1191","BK0239","BK1161","LU1997244956.HKD","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0456},{"period":"1month","weight":0.68},{"period":"3month","weight":1.0826},{"period":"6month","weight":1.8315},{"period":"1year","weight":1.5979},{"period":"ytd","weight":1.5979}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.1615},{"period":"6month","weight":0.2639},{"period":"1year","weight":0.5018},{"period":"ytd","weight":0.2743}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.128353},{"month":8,"riseRate":0.2,"avgChangeRate":-0.059234},{"month":9,"riseRate":0.2,"avgChangeRate":-0.170155},{"month":10,"riseRate":0.2,"avgChangeRate":-0.081213},{"month":11,"riseRate":0.6,"avgChangeRate":0.071209},{"month":12,"riseRate":0.2,"avgChangeRate":-0.215118}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}